Anti-hCD20-mIgG2a Monoclonal mouse IgG2a antibody against human CD20 Anti-hCD20-mIgG2a features the constant region of the mouse IgG2a isotype and the variable region of rituximab. Rituximab is a mouse/human chimeric monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B lymphocytes. Binding of rituximab to CD20 results in cell destruction through different mechanisms including direct signaling of apoptosis, complement activation and cell-mediated cytotoxicity. Rituximab has been approved by the FDA for the treatment of various lymphoid malignancies, including B-cell non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukaemia. Anti-hCD20-mIgG2a was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with protein G. Clonality: Monoclonal antibody Specificity: Targets cells expressing human CD20 Isotype: Mouse IgG2a